2026 Q2 - tulosraportti
60 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 5 | - | - | ||
| 14 | - | - | ||
| 1 | - | - | ||
| 750 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·9 t sittenAnalyst comment 19.10.2026, 08.54 Victor Skriver Equity Research Assistant At BioPorto's investor meeting on 7 October, Professor Dr. Jun Oh from Heidelberg University Hospital gave an independent clinical perspective on what the updated KDIGO guidelines mean for NGAL. His point was that nephrology is moving from reaction towards prevention, and that is precisely the shift upon which the investment case rests. Oh's presentation speaks directly into the second pillar of our investment case, where inclusion in KDIGO is the trigger for broader adoption in hospitals, and it supports the health economics angle, which we see as the most overlooked part of the case. BioPorto: From reaction to prevention in acute myocardial infarction - by Michael Friis, Head of Equities https://www.inderes.dk/videos/bioporto-from-reaction-to-prevention-in-aki Victor Skriver Equity Research Assistant https://www.inderes.dk/analyst-comments/dagens-aktienyheder-19102026-lundbeck-nordea-bioporto-og-greenmobility?utm_source=nordnet&utm_medium=integration
Thought-provoking with all the "positive" coverage, which is always delivered with HCA as the middleman. HCA naturally charges well for this service, and the money comes directly from the company's shareholders. - The circle is complete.- ·3 päivää sittenBioPorto: From reaction to prevention in acute myocardial infarction today at 13:28 ∙ Inderes https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationIt will be good for Bioporto when all the documents that KDIGO is currently working on are published, because it looks like most hospitals are waiting to get the NGAL test integrated into their treatment system until this work is finished. Is it wise to wait, I don't think so, if there are many who want the NGAL test at the same time.
- ·12.10.It seems that Bioporto has started to inform more on Linkedin than on their website about which fairs and conferences they are participating in. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/It also appears that the market is quite indifferent to all these trade fairs and conferences. The market lacks concrete progress in the business and the share price is slowly drifting down as a function of the company's dying patents and continuous losses
·9.10. · MuokattuPresentation from BioPorto at the investor conference in Odense on Oct. 8. https://konferencer.ugebrev.dk/event/ekstra-konference/ Scroll down the page. Located as the 3rd presentation.Many thanks for your post. They also mentioned the 60+ hospitals during the H1 webcast. That is also why I subsequently wrote here on Nordnet that I am sure that at this point it had already closed agreements with at least 7 hospitals or was on its way to doing so (the H1 webcast took place in the Q3 period). Therefore, my prediction is that when we reach Q4, they will say that in Q4 they are starting with 60+ hospitals.- ·8.10. · MuokattuBioPorto is on its way to ESICM LIVES 2026 in Lisbon! We look forward to connecting with the international intensive care community and participating in important conversations about acute kidney injury in critically ill patients. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/ We are at PPETS 2026 today! ( two days ago) BioPorto is in Houston, where the pediatric health community gathers to advance knowledge and share perspectives on extracorporeal therapies, including CRRT and ECMO.Bioporto has certainly been to a record number of trade fairs this year. It also makes sense, while they are waiting for KDIGO's revised documents to be released, that they are paving the way.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 146 258 | 146 258 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 146 258 | 146 258 | 0 | 0 |
2026 Q2 - tulosraportti
60 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sittenAnalyst comment 19.10.2026, 08.54 Victor Skriver Equity Research Assistant At BioPorto's investor meeting on 7 October, Professor Dr. Jun Oh from Heidelberg University Hospital gave an independent clinical perspective on what the updated KDIGO guidelines mean for NGAL. His point was that nephrology is moving from reaction towards prevention, and that is precisely the shift upon which the investment case rests. Oh's presentation speaks directly into the second pillar of our investment case, where inclusion in KDIGO is the trigger for broader adoption in hospitals, and it supports the health economics angle, which we see as the most overlooked part of the case. BioPorto: From reaction to prevention in acute myocardial infarction - by Michael Friis, Head of Equities https://www.inderes.dk/videos/bioporto-from-reaction-to-prevention-in-aki Victor Skriver Equity Research Assistant https://www.inderes.dk/analyst-comments/dagens-aktienyheder-19102026-lundbeck-nordea-bioporto-og-greenmobility?utm_source=nordnet&utm_medium=integrationThought-provoking with all the "positive" coverage, which is always delivered with HCA as the middleman. HCA naturally charges well for this service, and the money comes directly from the company's shareholders. - The circle is complete.
- ·3 päivää sittenBioPorto: From reaction to prevention in acute myocardial infarction today at 13:28 ∙ Inderes https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationIt will be good for Bioporto when all the documents that KDIGO is currently working on are published, because it looks like most hospitals are waiting to get the NGAL test integrated into their treatment system until this work is finished. Is it wise to wait, I don't think so, if there are many who want the NGAL test at the same time.
- ·12.10.It seems that Bioporto has started to inform more on Linkedin than on their website about which fairs and conferences they are participating in. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/It also appears that the market is quite indifferent to all these trade fairs and conferences. The market lacks concrete progress in the business and the share price is slowly drifting down as a function of the company's dying patents and continuous losses
- ·9.10. · MuokattuPresentation from BioPorto at the investor conference in Odense on Oct. 8. https://konferencer.ugebrev.dk/event/ekstra-konference/ Scroll down the page. Located as the 3rd presentation.Many thanks for your post. They also mentioned the 60+ hospitals during the H1 webcast. That is also why I subsequently wrote here on Nordnet that I am sure that at this point it had already closed agreements with at least 7 hospitals or was on its way to doing so (the H1 webcast took place in the Q3 period). Therefore, my prediction is that when we reach Q4, they will say that in Q4 they are starting with 60+ hospitals.
- ·8.10. · MuokattuBioPorto is on its way to ESICM LIVES 2026 in Lisbon! We look forward to connecting with the international intensive care community and participating in important conversations about acute kidney injury in critically ill patients. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/ We are at PPETS 2026 today! ( two days ago) BioPorto is in Houston, where the pediatric health community gathers to advance knowledge and share perspectives on extracorporeal therapies, including CRRT and ECMO.Bioporto has certainly been to a record number of trade fairs this year. It also makes sense, while they are waiting for KDIGO's revised documents to be released, that they are paving the way.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 5 | - | - | ||
| 14 | - | - | ||
| 1 | - | - | ||
| 750 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 146 258 | 146 258 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 146 258 | 146 258 | 0 | 0 |
2026 Q2 - tulosraportti
60 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sittenAnalyst comment 19.10.2026, 08.54 Victor Skriver Equity Research Assistant At BioPorto's investor meeting on 7 October, Professor Dr. Jun Oh from Heidelberg University Hospital gave an independent clinical perspective on what the updated KDIGO guidelines mean for NGAL. His point was that nephrology is moving from reaction towards prevention, and that is precisely the shift upon which the investment case rests. Oh's presentation speaks directly into the second pillar of our investment case, where inclusion in KDIGO is the trigger for broader adoption in hospitals, and it supports the health economics angle, which we see as the most overlooked part of the case. BioPorto: From reaction to prevention in acute myocardial infarction - by Michael Friis, Head of Equities https://www.inderes.dk/videos/bioporto-from-reaction-to-prevention-in-aki Victor Skriver Equity Research Assistant https://www.inderes.dk/analyst-comments/dagens-aktienyheder-19102026-lundbeck-nordea-bioporto-og-greenmobility?utm_source=nordnet&utm_medium=integrationThought-provoking with all the "positive" coverage, which is always delivered with HCA as the middleman. HCA naturally charges well for this service, and the money comes directly from the company's shareholders. - The circle is complete.
- ·3 päivää sittenBioPorto: From reaction to prevention in acute myocardial infarction today at 13:28 ∙ Inderes https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationIt will be good for Bioporto when all the documents that KDIGO is currently working on are published, because it looks like most hospitals are waiting to get the NGAL test integrated into their treatment system until this work is finished. Is it wise to wait, I don't think so, if there are many who want the NGAL test at the same time.
- ·12.10.It seems that Bioporto has started to inform more on Linkedin than on their website about which fairs and conferences they are participating in. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/It also appears that the market is quite indifferent to all these trade fairs and conferences. The market lacks concrete progress in the business and the share price is slowly drifting down as a function of the company's dying patents and continuous losses
- ·9.10. · MuokattuPresentation from BioPorto at the investor conference in Odense on Oct. 8. https://konferencer.ugebrev.dk/event/ekstra-konference/ Scroll down the page. Located as the 3rd presentation.Many thanks for your post. They also mentioned the 60+ hospitals during the H1 webcast. That is also why I subsequently wrote here on Nordnet that I am sure that at this point it had already closed agreements with at least 7 hospitals or was on its way to doing so (the H1 webcast took place in the Q3 period). Therefore, my prediction is that when we reach Q4, they will say that in Q4 they are starting with 60+ hospitals.
- ·8.10. · MuokattuBioPorto is on its way to ESICM LIVES 2026 in Lisbon! We look forward to connecting with the international intensive care community and participating in important conversations about acute kidney injury in critically ill patients. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/ We are at PPETS 2026 today! ( two days ago) BioPorto is in Houston, where the pediatric health community gathers to advance knowledge and share perspectives on extracorporeal therapies, including CRRT and ECMO.Bioporto has certainly been to a record number of trade fairs this year. It also makes sense, while they are waiting for KDIGO's revised documents to be released, that they are paving the way.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 5 | - | - | ||
| 14 | - | - | ||
| 1 | - | - | ||
| 750 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 146 258 | 146 258 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 146 258 | 146 258 | 0 | 0 |